KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2025)

Historic Research & Development for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $63.4 million.

  • Amneal Pharmaceuticals' Research & Development rose 369.09% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.6 million, marking a year-over-year increase of 1264.74%. This contributed to the annual value of $190.7 million for FY2024, which is 1632.45% up from last year.
  • Amneal Pharmaceuticals' Research & Development amounted to $63.4 million in Q3 2025, which was up 369.09% from $48.0 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Research & Development's 5-year high stood at $63.4 million during Q3 2025, with a 5-year trough of $36.1 million in Q2 2024.
  • For the 5-year period, Amneal Pharmaceuticals' Research & Development averaged around $47.6 million, with its median value being $48.2 million (2021).
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 2672.07% in 2023, then soared by 4766.65% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Research & Development (Quarter) stood at $51.9 million in 2021, then decreased by 19.21% to $41.9 million in 2022, then rose by 9.97% to $46.1 million in 2023, then increased by 17.75% to $54.3 million in 2024, then increased by 16.75% to $63.4 million in 2025.
  • Its last three reported values are $63.4 million in Q3 2025, $48.0 million for Q2 2025, and $40.0 million during Q1 2025.